文献速递淋巴瘤

实时全面分子检测在弥漫大B细胞淋巴瘤中的临床效用

Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2026-07-24

该先导研究评估了全外显子测序(WES)联合转录组测序(RNA-seq)在100例大B细胞淋巴瘤(LBCL)患者中的可行性和周转时间(TAT)。71例样本通过质控并完成分析,中位TAT为8天(范围6-22天),73%的报告在10天内交付。分子风险分类显示,24个月无事件生存(EFS24)高危特征与暗区特征(DZsig)和淋巴瘤微环境(LME)相关,但与细胞起源(COO)或LymphGen无关。

要点

  • WES联合RNA-seq在LBCL常规临床实践中可行,中位报告周转时间8天。
  • 基于DZsig和LME的分子分型可识别EFS24高危患者,而COO或LymphGen未显示关联。
  • 整合分子检测有望指导新线治疗决策并支持基于生物学亚型的临床试验。

核心结论

  • 在LBCL患者中,全面WES和RNA-seq检测具有临床可行性且周转时间可接受。
  • 分子风险分类中,EFS24高危特征与DZsig和LME相关,但与COO或LymphGen无关。

研究设计与样本

  • 先导研究(NCT05464823),纳入年龄≥18岁的LBCL患者,对诊断或复发时的FFPE组织进行WES、RNA-seq和拷贝数分析,并同步进行胚系DNA测序。

主要发现

  • 100例入组患者中,71例(48例初诊,23例复发/难治)样本通过病理质控并完成WES和RNA-seq分析及报告。
  • 个体患者报告的中位周转时间为8天(范围6-22天),73%的报告在≤10天内交付。
  • 应用分子风险分类,24个月无事件生存(EFS24)高危特征与DZsig和LME相关,但与COO或LymphGen无关。

临床怎么用

  • 在LBCL新线治疗决策时,可考虑采用整合WES和RNA-seq的全面分子检测来定义分子亚组。
  • 该检测方法可用于指导基于生物学亚型的临床试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Due to the rapidly evolving landscape of targeted therapies, there is an unmet need for comprehensive molecular profiling to guide treatment decisions for patients with large B-cell lymphoma (LBCL). Therefore, we designed a pilot study to assess the feasibility and turnaround time (TAT) of a comprehensive whole exome sequencing (WES) and transcriptome sequencing (RNA-seq) assay in patients with LBCL (NCT05464823). Patients aged ≥18 years with LBCL were eligible. Formalin-fixed paraffin-embedded tissues at diagnosis or recurrence underwent WES, RNA-seq, and copy number analysis with concomitant germline DNA sequencing. Genomic and transcriptomic data were profiled to define various LBCL signatures such as cell-of-origin (COO), dark zone signature (DZsig), LymphGen and lymphoma microenvironment (LME) classification. Among 100 patients enrolled, samples from 71 patients (48 with newly diagnosed and 23 with relapsed/refractory disease) passed pathology quality control and underwent WES and RNA-seq analysis and reporting. The median TAT was 8 days for individual patient reports (range: 6-22 days), with 73% of reports delivered ≤10 days. Applying molecular risk classification, high risk event-free survival within 24 months (EFS24) signature was associated with DZsig and LME, but not with COO or LymphGen indicating the complex heterogeneity of the disease. We demonstrated the clinical utility and acceptable TAT of a comprehensive WES and RNA-seq assay for LBCL managed in routine clinical practice. These findings support the real-world feasibility of using integrated WES and RNA-seq to define molecular subgroups, guide clinical decision-making at the time of a new line of therapy, and enable biology based subtype-driven clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chihara D, Balakrishnan K, Masand G, et al. Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma. Blood Adv. 2026. PMID: 42498283. doi:10.1182/bloodadvances.2025019468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。